ALNYLAM PHARMACEUTICALS, INC.
At today's price, ALNYLAM PHARMACEUTICALS, INC. (ALNY) is priced for today's economics sustained for ~7.1 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Alnylam is the company that turned RNA interference from a Nobel-winning idea into approved medicines, and its lead drug AMVUTTRA is inflecting hard: total TTR net product revenue reached $910 million in the first quarter of 2026, up 153% year over year after the drug's label expanded into heart disease [Source: Q1 FY2026 earnings release]. • The price is a durability bet, not a value one: at over forty times book value, only the methods that project years of fast growth reach it, so a holder
Is ALNY overvalued? See what's priced in →
765 institutional managers reported holding ALNY in 13F filings for the quarter ended 2026-03-31. Together they hold about 90% of the company; the top 10 hold 54%. 89 opened new positions that quarter. Held by FMR (Fidelity), Vanguard Group, Capital Group (American Funds), among others. On the short side, 5.4M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (4.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ALNY's share count grew 11.6% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at ALNY over the trailing three years: 2024: 2 buys totaling $10k. 18 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ALNY's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-05 | +6.3% | -9.1% |
| 2023-08-04 | -0.8% | -4.7% |
| 2023-11-03 | +6.6% | +13.2% |
| 2024-02-16 | -10.4% | -1.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ALNY's latest 8-K filings: 2026-05-27 (items 5.02, 5.07); 2026-04-30 (items 2.02, 9.01); 2026-03-04 (items 5.02); 2026-02-12 (items 2.02, 9.01); 2026-01-12 (items 2.02).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 3, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.